@comment{{This file has been generated by bib2bib 1.96}}
@comment{{Command line: /usr/bin/bib2bib -oc all -ob all.bib -c 'not volume : "submitted"' -s ’’ ../ref_pubs.bib ../ab_pubs.bib ../misc_pubs.bib}}
@comment{{jabref-meta: selector_publisher:}}
@comment{{jabref-meta: selector_author:}}
@comment{{jabref-meta: selector_journal:}}
@comment{{jabref-meta: selector_keywords:}}
@comment{{jabref-meta: selector_publisher:}}
@comment{{jabref-meta: selector_author:}}
@comment{{jabref-meta: selector_journal:}}
@comment{{jabref-meta: selector_keywords:}}
@comment{{jabref-meta: selector_publisher:}}
@comment{{jabref-meta: selector_author:}}
@comment{{jabref-meta: selector_journal:}}
@comment{{jabref-meta: selector_keywords:}}
@article{AeberliEtAl2011,
author = {I Aeberli and P A Gerber and M Hochuli and S Kohler and S R \textbf{Haile}
and I Gouni-Berthold and H K Berthold and G A Spinas and K Berneis},
title = {{L}ow to moderate sugar-sweetened beverage consumption impairs glucose
and lipid metabolism and promotes inflammation in healthy young men:
a randomized controlled trial.},
journal = {American Journal of Clinical Nutrition},
year = {2011},
volume = {94},
pages = {479--485},
number = {2},
month = {August},
abstract = {Background: Sugar-sweetened beverages ({SSB}s) have unfavorable effects
on glucose and lipid metabolism if consumed in high quantities by
obese subjects, but the effect of lower doses in normal-weight subjects
is less clear.
Objective: The aim was to investigate the effects of {SSB}s consumed
in small to moderate quantities for 3 wk on {LDL} particle distribution
and on other parameters of glucose and lipid metabolism as well as
on inflammatory markers in healthy young men.
Design: Twenty-nine subjects were studied in a prospective, randomized,
controlled crossover trial. Six 3-wk interventions were assigned
in random order as follows: 600 m{L} {SSB}s containing 1)40 g fructose/d
[medium fructose ({MF})], 2) 80 g fructose/d [high fructose ({HF})],
3) 40 g glucose/d [medium glucose ({MG})], 4) 80 g glucose/d [high
glucose ({HG})], 5) 80 g sucrose/d [high sucrose ({HS})], or 6) dietary
advice to consume low amounts of fructose. Outcome parameters were
measured at baseline and after each intervention.
Results: {LDL} particle size was reduced after {HF} by -0.51 nm (95\%
CI: -0.19, -0.82 nm) and after {HS} by -0.43 nm (95\% CI: -0.12,
-0.74; P < 0.05 for both). Similarly, a more atherogenic {LDL} subclass
distribution was seen when fructose-containing {SSB}s were consumed
({MF}, {HF}, and {HS}: P < 0.05). Fasting glucose and high-sensitivity
{C}-reactive protein (hs-{CRP}) increased significantly after all
interventions (by 4-9\% and 60-109\%, respectively; P < 0.05); leptin
increased during interventions with {SSB}s containing glucose only
({MG} and {HG}: P < 0.05).
Conclusion: The present data show potentially harmful effects of low
to moderate consumption of {SSB}s on markers of cardiovascular risk
such as LDL particles, fasting glucose, and hs-{CRP} within just
3 wk in healthy young men, which is of particular significance for
young consumers. This trial was registered at clinicaltrials.gov
as NCT01021969.},
doi = {10.3945/ajcn.111.013540},
owner = {sarah},
timestamp = {2011.06.17}
}
@article{Broglie2011,
author = {Broglie, M A and \textbf{Haile}, S R and St\"ockli, S J},
title = {{L}ong-{T}erm {E}xperience in {S}entinel {N}ode {B}iopsy for {E}arly
{O}ral and {O}ropharyngeal {S}quamous {C}ell {C}arcinoma},
journal = {Annals of Surgical Oncology},
year = {2011},
volume = {18},
pages = {2732--2738},
number = {10},
abstract = {OBJECTIVE: Long-term results of sentinel node biopsy (SNB) in early
(T1/T2) oral and oropharyngeal squamous cell carcinoma (OSCC) in
a single-institution experience.
METHODS: Prospective consecutive cohort analysis of 79 patients (67\%
male, median age 60 years, age range 34-87 years) included between
2000 and 2006. Lymphatic mapping consisted of preoperative lymphoscintigraphy,
single photon emission computed tomography (SPECT/CT), and intraoperative
use of a handheld gamma probe. Endpoints of the study were neck control
rate, overall (OS), disease-specific (DSS), and disease-free survival
(DFS).
RESULTS: Twenty-nine of 79 patients (37\%) had positive sentinel nodes
(SN). Six of 29 (21\%) patients showed isolated tumor cells, 14/29
(48\%) micrometastases, and 9/29 (31\%) macrometastases. OS, DFS,
and DSS at 5 years for the entire cohort were 80, 85, and 87\%, for
SN-negative patients were 88, 96, and 96\%, and for SN-positive patients
were 74, 73, and 77\%, respectively. Only the difference in DSS achieved
statistical significance. The neck control rate after 5 years was
96\% in SN-negative and 74\% in SN-positive patients. This difference
was statistically significant.
CONCLUSIONS: SNB is a safe and accurate staging modality to select
patients with clinically stage I/II OSCC with occult lymph node disease
for elective neck dissection (END). The promising reported short-term
results have been sustained by long-term follow-up. Patients with
negative SN and no END achieve an excellent neck control rate which
compares favorably with reports on primary END. The neck control
rate in SN-negative patients is superior to that in SN-positive patients,
which is reflected in superior DSS.},
doi = {10.1245/s10434-011-1780-6},
file = {:/home/sarah/ispm/pubs/Broglie2011.pdf:PDF},
owner = {sarah},
timestamp = {2011.05.20}
}
@article{EnseleitEtAl2012,
author = {F Enseleit and I Sudano and D P\'eriat and S Winnik and M Wolfrum
and S R \textbf{Haile} and N Krasniqi and C M Matter and K Uhlenhut
and P H\"ogger and M Neidhart and T F L\"uscher and F Ruschitzka
and G Noll},
title = {{E}ffects of {P}ycnogenol on {E}ndothelial {F}unction in {P}atients
with {S}table {C}oronary {A}rtery {D}isease -- {A} {D}ouble-blind,
{R}andomized, {P}lacebo-controlled, {C}rossover {S}tudy},
journal = {European Heart Journal},
year = {2012},
volume = {to appear},
abstract = {Aims: Extracts from pine tree bark containing a variety of flavonoids
have been used in traditional medicine. Pycnogenol is a proprietary
bark extract of the French maritime pine tree (Pinus pinaster ssp.
atlantica) that exerts antioxidative, anti-inflammatory, and anti-platelet
effects. However, the effects of Pycnogenol on endothelial dysfunction,
a precursor of atherosclerosis and cardiovascular events, remain
still elusive.
Methods and results: Twenty-three patients with coronary artery disease
(CAD) completed this randomized, double-blind, placebo-controlled
cross-over study. Patients received Pycnogenol (200 mg/day) for 8
weeks followed by placebo or vice versa on top of standard cardiovascular
therapy. Between the two treatment periods, a 2-week washout period
was scheduled. At baseline and after each treatment period, endothelial
function, non-invasively assessed by flow-mediated dilatation (FMD)
of the brachial artery using high-resolution ultrasound, biomarkers
of oxidative stress and inflammation, platelet adhesion, and 24 h
blood pressure monitoring were evaluated. In CAD patients, Pycnogenol
treatment was associated with an improvement of FMD from 5.3 +/-
2.6 to 7.0 +/- 3.1 (P < 0.0001), while no change was observed with
placebo (5.4 +/- 2.4 to 4.7 +/- 2.0; P = 0.051). This difference
between study groups was significant [estimated treatment effect
2.75; 95\% confidence interval (CI): 1.75, 3.75, P < 0.0001]. 15-F2t-Isoprostane,
an index of oxidative stress, significantly decreased from 0.71 +/-
0.09 to 0.66 +/- 0.13 after Pycnogenol treatment, while no change
was observed in the placebo group (mean difference 0.06 pg/mL with
an associated 95\% CI (0.01, 0.11), P = 0.012]. Inflammation markers,
platelet adhesion, and blood pressure did not change after treatment
with Pycnogenol or placebo.
Conclusion: This study provides the first evidence that the antioxidant
Pycnogenol improves endothelial function in patients with CAD by
reducing oxidative stress.
Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00641758},
doi = {10.1093/eurheartj/ehr482},
file = {:/home/sarah/ispm/pubs/Eur Heart J-2012-Enseleit-eurheartj-ehr482.pdf:PDF},
owner = {sarah},
timestamp = {2011.12.07}
}
@article{FeldmeyerEtAl2010,
author = {Feldmeyer, L and Benden, C and \textbf{Haile}, S R and Boehler, A
and Speich, R and French, L E and Hofbauer, G F L},
title = {{N}ot {A}ll {I}ntravenous {I}mmunoglobulin {P}reparations are {E}qually
{W}ell {T}olerated},
journal = {Acta Dermato Venereologica},
year = {2010},
volume = {90},
pages = {494--497},
number = {5},
__markedentry = {[sarah]},
abstract = {Intravenous immunoglobulin (IVIG) is used for many indications beyond
the original substitution in primary antibody deficiency. Whereas
many reports mention adverse reactions, no comparative data exist
concerning the incidence of side-effects among the different brands
of IVIG. We describe here our experience with the use of different
IVIG formulations and their tolerability in a select cohort of 40
patients. The IVIG dose ranged from 0.4 to 3 g/kg/day and was given
for 1–2742 days. Fourteen patients (35\%) experienced mild to severe
adverse reactions during or within 48 h of administration of standard
IVIG preparation, which did not recur after switching to an alternative
preparation. Adverse reactions included headache, fever, chills,
nausea, emesis, hypotension and muscle cramps. One patient experienced
a severe adverse reaction; he had a 3-day headache following IVIG
infusion. Among the 16 patients who received alternative preparation
initially, none experienced adverse reactions. In conclusion, this
study shows that IVIG preparations are not all equally well tolerated
in patients. The data suggest that, perhaps to a comparable extent
to the preparation itself, the infusion rate has a major effect.
If a reduction in the infusion rate does not minimize sideeffects,
one should consider switching the IVIG formulation.},
comment = {IF 3.007, ZORA},
doi = {10.2340/00015555-0900},
file = {:/home/sarah/ispm/pubs/FeldmeyerEtAl2010_ActaDermatoVen.pdf:PDF},
keywords = {intravenous immunoglobulin; adverse drug reaction; prevention; toxic
epidermal necrolysis; hypogammaglobulinaemia; lung transplantation.},
owner = {sarah},
timestamp = {2010.09.02}
}
@article{ForsterEtAl2012,
author = {N A Forster and D G Nunez and M Zingg and S R \textbf{Haile} and
W Kuenzi and P Giovanoli and M Guggenheim},
title = {{A}ttempted suicide by self-immolation is a powerful predictive variable
for survival of burn injuries},
journal = {Journal of Burn Care \& Research},
year = {2012},
volume = {to appear},
abstract = {Objective: Up to 9\% of all burn injuries in western countries are
been reported to have been caused by self-immolation with suicidal
intent and usually involve extensive injuries. We sought to identify
differences between suicide burn victims as opposed to those who
sustained their injuries accidentally, with regards to injury severity
and mortality and determine the possible impact of suicide as a prognostic
variable in the context of
a scoring system such as the Abbreviated Burns Severity Index (ABSI).
Patients and Methods: The data of all burns patients treated at the
Specialist Burns Intensive Care Unit, University Hospital Zurich,
between 1968 and 2008 were analysed retrospectively.
Results: Of the 2813 patients included in the study, 191 were identified
as attempted suicides, most commonly involving the use of accelerants.
30\% of all suicide victims had pre-existing psychiatric diagnoses.
Suicide victims presented with significantly more extensive burns
(53.7\%, +/- 0.98 SEM versus 21.4\%, +/- 0.36 SEM, p <0.0001), had
higher total ABSI scores (8.4, +/-0.23 SEM versus 6.6, +/- 0.05 SEM,
p< 0.0001) and higher mortality rates (42.9\% (83/191) versus 16.3\%
(426/2622)) than accident victims. Furthermore logistic regression
revealed suicide to be as significant a predictor of mortality as
inhalation injury (OR 2.2, 95\% CI 1.4-3.5, p< 0.0003 and OR 2.4,
95\% CI 1.4-4.0, p<0.0009, respectively).
Conclusions: The odds of dying from an attempted suicide are twice
as high compared to those of accident patients in the same ABSI category,
making suicide a powerful predictor of mortality. We therefore suggest
including it as a fixed variable in scoring systems for estimating
a patient's mortality after burn injuries, such as the widely used
ABSI.},
doi = {10.1097/BCR.0b013e3182479b28},
owner = {sarah},
timestamp = {2011.12.13}
}
@article{ForsterEtAl2011,
author = {N A Forster and M Zingg and S R \textbf{Haile} and W K\"unzi and
P Giovanoli and M Guggenheim},
title = {30 years later -- {D}oes the {ABSI} need revision?},
journal = {Burns},
year = {2011},
volume = {37},
pages = {958--963},
number = {6},
month = {September},
abstract = {In light of changes in patient demographics together with constant
developments in burn care, the predictive accuracy of the Abbreviated
Burns Severity Index (ABSI) -- first described in 1982 -- for estimating
the mortality of present day burns patients, may be questionable.
We reviewed the records of 2813 burns patients treated between January
1968 and December 2008 in the intensive care unit at our institution,
aiming to identify emerging discrepancies between the estimated and
calculated outcome, based on each of the ABSI variables and the total
burn score. The predictive value of each of the defined ABSI variables
was confirmed to be highly significant. Univariable and multivariable
analysis revealed an exponential increase in odds ratio (OR) for
mortality for patients older than 60 years and more than 30\% TBSA
burned and showed OR values over 10 times higher than other significant
variables like inhalation injury. Nevertheless, the ABSI for the
estimation of mortality in our entire patient collective was highly
accurate and could not be optimised by adapting the point distribution
to the increase in OR. Our data indicates that despite significant
changes in patient demographics and medical advances over the past
30 years, the ABSI scoring system is still an accurate and valuable
tool in the prediction of burn patient mortality.},
doi = {10.1016/j.burns.2011.03.009},
owner = {sarah},
timestamp = {2011.04.04}
}
@article{HaeuptleEtAl2012,
author = {R H\"auptle and D Weilenmann and T Schneider and S R \textbf{Haile}
and P Ammann and C Knellwolf and J Borovicka},
title = {{I}ndividualised proton pump inhibitors ({PPI}) prescription in patients
on combination antiplatelet therapy and upper gastrointestinal events
after percutaneous coronary intervention: {A} cohort study},
journal = {Wiener klinische Wochenschrift},
year = {2012},
volume = {to appear},
abstract = {Questions under study: We investigated the effect of individualised
proton pump inhibitors (PPI) prescription on upper gastrointestinal
adverse events in a cohort of patients who received combination antiplatelet
therapy (aspirin and clopidogrel) after percutaneous coronary intervention
(PCI).
Methods: Upper gastrointestinal risk factors and other parameters
were extracted from a dedicated electronic database. Patients were
contacted with a standardised questionnaire. A structured phone interview
was performed in all patients with upper gastrointestinal adverse
events.
Results: A cohort of 718 patients on combination therapy yielded 87
(12.1\%) patients with prophylactic PPI treatment. Upper gastrointestinal
adverse events occurred in 18.4\% patients with and in 11.1\% patients
without prophylactic PPI (OR 1.80, P=0.054). Co-treatment with corticosteroids
was the main identifiable risk factor for upper gastrointestinal
adverse events (adjusted OR 5.45, P=0.014).
Conclusion: Individualised prescription of PPI-prophylaxis after PCI
in patients on combined antiplatelet therapy based on risk assessment
for upper gastrointestinal-bleeding seems to represent an effective
measure to minimise upper gastrointestinal adverse events after PCI.},
owner = {sarah},
timestamp = {2012.01.23}
}
@article{JulianEtAl2007,
author = {T B Julian and S R Land and V Fourchotte and S R \textbf{Haile} and
E R Fisher and E P Mamounas and J P Costantino and N Wolmark},
title = {{I}s sentinel node biopsy necessary in conservatively treated {DCIS}?},
journal = {Annals of Surgical Oncology},
year = {2007},
volume = {14},
pages = {2202 -- 8},
number = {8},
__markedentry = {[sarah]},
abstract = {BACKGROUND: We sought to identify the risk of axillary node involvement
in patients with ductal carcinoma in situ (DCIS) and to determine
whether axillary node assessment is necessary in these patients.
Sentinel node biopsy (SNB) is replacing standard axillary lymph node
dissection (ALND) for surgical staging of invasive breast cancer.
Its use in patients with DCIS versus local excision (LE), observation,
and/or breast irradiation remains in question. METHODS: We examined
the records of 813 patients with localized DCIS and disease-negative
margins after LE who were randomly assigned to no further therapy
or to breast irradiation in National Surgical Adjuvant Breast and
Bowel Project (NSABP) trial B-17 and 1799 patients randomized to
receive placebo or tamoxifen after LE + radiotherapy in NSABP trial
B-24. An ALND was performed in 253 patients in NSABP B-17 and in
162 in NSABP B-24. RESULTS: We found that in NSABP trial B-17, seven
patients developed ipsilateral nodal recurrence (INR). Overall INR
rate was 0.83/1000 patient-years. In NSABP B-24, overall INR rate
was 0.36/1000 patient-years. INR can be considered a surrogate for
axillary involvement at the time of DCIS diagnosis. CONCLUSIONS:
INR in patients with DCIS treated conservatively is extremely rare.
Our findings do not support the routine use of SNB in patients with
conservatively treated, localized DCIS.},
comment = {IF 4.13},
doi = {10.1245/s10434-007-9353-4},
owner = {haile},
timestamp = {2007.12.01}
}
@article{LandEtAl2007,
author = {S R Land and M W Ritter and J P Costantino and T B Julian and W M
Cronin and S R \textbf{Haile} and N Wolmark and P A Ganz},
title = {{C}ompliance with patient-reported outcomes in multicenter clinical
trials: methodologic and practical approaches},
journal = {Journal of Clinical Oncology},
year = {2007},
volume = {25},
pages = {5113 -- 20},
number = {32},
month = {November 10},
__markedentry = {[sarah]},
abstract = {PURPOSE: This report describes interventions undertaken by the National
Surgical Adjuvant Breast and Bowel Project (NSABP) to improve compliance
with patient-reported outcome (PRO) assessments in the setting of
multicenter cancer clinical trials. We describe the effectiveness
of several interventions and of observational factors. METHODS: PRO
submission rates were analyzed for the following three NSABP protocols:
the Study of Raloxifene and Tamoxifen (STAR), B-32, and B-35. Institutions
participating in protocol B-35 were randomly assigned to receive
automated reminders of upcoming assessments or not. Compliance was
analyzed with a logistic repeated measures mixed modeling. RESULTS:
Compliance was high in the three protocols, with rates greater than
80\% for nearly all time points. Institutions were a significant
source of variability (P < .01). The largest institutions had the
highest compliance in STAR (odds ratio [OR] = 0.68 for $<$ 50 participants
enrolled and OR = 0.82 for 50 to 99 participants enrolled v larger
institutions; P < .001). Midsized institutions had highest compliance
in B-32 (OR = 4.63 for 31 to 50 patients enrolled and OR = 3.12 for
> 50 patients enrolled v small institutions; P = .007). Compliance
increased with participant age in STAR (OR = 0.57, 0.89, and 1.01
for ages < 50, 50 to 60, and 60 to 70 years, respectively, v > 70
years; P < .001). Race was significant in B-32 (OR = 2.63 for white
v nonwhite; P < .001) and in STAR (OR = 1.41 for white v nonwhite;
P < .001). Treatment group was significant in B-32 (OR = 0.74; P
= .006). The B-35 prospective reminder did not improve compliance
significantly (P = .30), but in B-32, delinquency sanctions were
significant (OR = 1.56; P = .007). CONCLUSION: Compliance in NSABP
PRO studies is higher now than a decade ago. Results for compliance
initiatives were mixed. Age and race are important factors, but institutional
variation remains significant and largely unexplained.},
comment = {IF 17.93},
doi = {10.1200/JCO.2007.12.1749},
owner = {haile},
timestamp = {2007.12.01}
}
@article{MeierEtAl2011,
author = {T O Meier and M Guggenheim and S T Vetter and M Husman and S R \textbf{Haile}
and B R Amann-Vesti},
title = {{M}icrovascular regeneration in meshed skin transplants after severe
burns},
journal = {Burns},
year = {2011},
volume = {37},
pages = {1010--14},
number = {6},
month = {September},
abstract = {Function of the skin lymphatics as well as blood perfusion of a meshed
transplant is crucial for the healing. The lymphatic regeneration
and arterial perfusion of skin transplants after severe burns of
the extremities had been studied in eight patients by microlymphography,
laser doppler perfusion imaging and transcutaneous oxygen pressure
measurements 1, 6 and 18 months after transplantation. One month
after transplantation, only fragmented as well as many giant lymphatic
skin vessels were present in the transplant. After 6 months a normal
lymphatic network had developed in all grafts. The extension of the
dye in the lymphatics decreased from 4.5 (0-16) at 1 month to 3.0
(1-6) mm after 18 months, indicating improved lymph drainage capacity.
The permeability of the lymphatics in the graft was normal. After
1 month, median laser flux in the transplant was 155.6\% (105-246\%)
of the normal skin but it normalised within 18 months. By contrast,
transcutaneous oxygen measurement (TcPO(2)) increased from 44 (21-47)
to 55 (50-76) mmHg. In meshed transplants used to cover severely
burned skin morphological and functional normal lymphatics develop
within 6 months and the initially increased laser flux due to inflammatory
reaction normalises. Our results provide important insights into
the healing process of skin transplants after burn.},
doi = {10.1016/j.burns.2011.01.001},
owner = {sarah},
timestamp = {2011.04.08}
}
@article{MurerEtAl2011,
author = {K Murer and G Huber and S R \textbf{Haile} and S St\"ockli},
title = {{C}omparison of morbidity between sentinel node biopsy and elective
neck dissection for treatment of the {N0} neck in patients with oral
squamous cell carcinoma},
journal = {Head and Neck},
year = {2011},
volume = {33},
pages = {1260--4},
number = {9},
month = {September},
__markedentry = {[sarah]},
abstract = {Background. Sentinel node biopsy ({SNB}) has been proposed for staging
of the {cN0} neck in early oral/oropharyngeal squamous cell carcinomas
({SCC}). As {SNB} is a minimally invasive procedure, it is thought
to be associated with less morbidity than elective neck dissection.
Methods. Sixty-two consecutive patients were included from 2000 to
2009. Two groups were analyzed consisting of 33 patients after SNB
and 29 after elective neck dissection. Subjective impairment and
functional shoulder status were assessed with the {Neck Dissection
Impairment Index} ({NDII}) questionnaire and the modified individual
relative Constant Score. Postoperative complications were retrieved
from the clinical charts.
Results. The investigated scores were significantly better in the
{SNB} group. All postoperative complications occurred in the elective
neck dissection group.
Conclusion. {SNB} is associated with significantly less postoperative
morbidity and better shoulder function than elective neck dissection.
This supports our opinion that patients with nodal negative early
{SCC} of the oral cavity should be offered {SNB}.},
comment = {IF 2.28},
doi = {10.1002/hed.21622},
file = {:/home/sarah/ispm/pubs/MurerEtAl2011HeadNeck.pdf:PDF},
owner = {sarah},
timestamp = {2010.09.07}
}
@article{PetrauschEtAl2010,
author = {U Petrausch and P Samaras and S R \textbf{Haile} and P Veit-Haibach
and J D Soyka and A Knuth and T F Hany and A Mischo and C Renner
and N G Sch\"aefer},
title = {{R}isk-adapted {FDG-PET}/{CT}-based follow-up in patients with diffuse
large {B}-cell lymphoma after first-line therapy},
journal = {Annals of Oncology},
year = {2010},
volume = {21},
pages = {1694--8},
number = {8},
month = {August},
__markedentry = {[sarah]},
abstract = {Background: The purpose of this study was to evaluate the impact of
2-[fluorine-18]fluoro-2-deoxy-{D}-glucose–positron emission tomography/computed
tomography ({FDG-PET}/{CT}) during follow-up of patients with diffuse
large {B}-cell lymphoma ({DLBCL}) being in complete remission or
unconfirmed complete remission after first-line therapy.
Patients and methods: {DLBCL} patients receiving {FDG-PET}/{CT} during
follow-up were analyzed retrospectively. Confirmatory biopsy was
mandatory in cases of suspected disease recurrence.
Results: Seventy-five patients were analyzed and 23 (30\%) had disease
recurrence. The positive predictive value ({PPV}) of {FDG-PET}/{CT}
was 0.85. Patients >60 years [P = 0.036, hazard ratio ({HR}) = 3.82,
95\% confidence interval ({CI}) 1.02-7.77] and patients with symptoms
indicative of a relapse (P = 0.015; {HR} = 4.1; 95\% {CI} 1.20-14.03)
had a significantly higher risk for relapse. A risk score on the
basis of signs of relapse, age >60 years, or a combination of these
factors identified patients at high risk for recurrence ({P} = 0.041).
Conclusions: {FDG-PET}/{CT} detects recurrent {DLBCL} after first-line
therapy with high PPV. However, it should not be used routinely and
if only in selected high-risk patients to reduce radiation burden
and costs. On the basis of our retrospective data, {FDG-PET}/{CT}
during follow-up is indicated for patients <60 years with clinical
signs of relapse and in patients >60 years with and without clinical
signs of relapse.},
comment = {ZORA, IF 5.647},
doi = {10.1093/annonc/mdq015},
file = {:/home/sarah/ispm/pubs/PetrauschEtAl2010_AnnalsOncology.pdf:PDF},
owner = {sarah},
timestamp = {2010.02.08}
}
@article{SamarasEtAl2011smw,
author = {P Samaras and M Blickenstorfer and S R \textbf{Haile} and D Siciliano
and U Petrausch and A Mischo and M Zweifel and H Honegger and U Schanz
and G St\"ussi and C Taverna and S Bauer and A Knuth and F Stenner-Liewen
and C Renner},
title = {{V}alidation of prognostic factors and survival of patients with
multiple myeloma in a real-life autologous stem cell transplantation
setting: a {S}wiss single centre experience.},
journal = {Swiss Medical Weekly},
year = {2011},
volume = {141},
pages = {w13203},
month = {May},
abstract = {PRINCIPLES: High-dose chemotherapy with subsequent autologous stem
cell transplantation ({ASCT}) is an important treatment option in
younger patients with multiple myeloma ({MM}). We analysed the outcome
of patients treated at our institution outside the clinical trials
framework and tried to identify risk factors prognostic for survival.
METHODS: Medical histories of the patients were screened for response,
event-free survival ({EFS}) and overall survival ({OS}). Pre-transplant
variables were analysed to identify possible prognostic risk factors.
RESULTS: Overall, 182 {ASCT} were performed in 120 patients with {MM}
from 2002 to 2007. Treatment-related mortality ({TRM}) was 0.5\%.
Median {EFS} was 23.1 months (95\% confidence interval [{CI}]: 19.4
- 28.4) and median {OS} was 49.8 months (95\%{CI}: 43.7 - not reached)
in the whole patient population. The median {OS} in patients who
received one {ASCT} was 46.4 months (95\%{CI}: 35.2 - not reached),
and 63.7 months (95\%{CI}: 48.9 - not reached) in patients who underwent
double {ASCT}.
Patients who already achieved a complete remission ({CR}) before {ASCT}
had a longer {EFS} (p = 0.016) than patients without {CR}. Additionally,
patients who achieved a {CR} after {ASCT} had a longer {EFS} (p =
0.0061) and {OS} (p = 0.0024) than patients without {CR}. {ISS} stage
<{III} at first diagnosis strongly correlated with improved {EFS}
(p = 0.0006) and {OS} (p <0.0001).
CONCLUSIONS: {ASCT} is a safe and effective treatment mode in eligible
patients with {MM}. {TRM} was below average at our institution. Achievement
of {CR} after transplantation was the most valuable predictor for
improved overall survival.},
doi = {10.4414/smw.2011.13203},
file = {:/home/sarah/ispm/pubs/SamarasEtAl2011_SwissMedWeekly.pdf:PDF},
owner = {sarah},
timestamp = {2011.06.13}
}
@article{SamarasEtAl2011,
author = {P Samaras and M Blickenstorfer and R Siciliano and S R \textbf{Haile}
and E Buset and U Petrausch and A Mischo and H Honegger and U Schanz
and G Stussi and R Stahel and A Knuth and F Stenner-Liewen and C
Renner},
title = {{P}egfilgrastim reduces the length of hospitalization and the time
to engraftment in multiple myeloma patients treated with melphalan
200 and auto-{SCT} compared with filgrastim},
journal = {Annals of Hematology},
year = {2011},
volume = {90},
pages = {89-94},
__markedentry = {[sarah]},
abstract = {To reduce the duration of neutropenia after conditioning chemotherapy
and autologous peripheral blood stem cell transplantation (APBSCT),
granulocyte-colony stimulating factors (G-CSF) are commonly administered.
We retrospectively evaluated the impact of pegfilgrastim compared
to filgrastim on neutrophil engraftment, hospital stay, and supportive
measures in patients with multiple myeloma after conditioning with
Melphalan 200 (Mel200) followed by APBSCT. Ninety-two APBSCT after
Mel200 treatment were performed in 72 patients between January 2006
and December 2009 at our institution. Patients received either single-dose
pegfilgrastim (n=46; 50\%), or daily filgrastim (n=46; 50\%) after
APBSCT (median duration of filgrastim use, 9 days; range, 3-14 days).
Duration of neutropenia grade IV was shorter with pegfilgrastim compared
with filgrastim (median, 5 days (range, 3-14 days) versus 6 days
(range, 3-9 days), p=0.0079). The length of hospitalization differed
significantly (pegfilgrastim (median, 14.5 days; range, 11-47 days)
versus filgrastim (median, 15.5 days; range, 12-64 days), p=0.024).
Pegfilgrastim-treated patients had less red blood cell transfusions
(median, 0 transfusions (range, 0-10) versus 0.5 transfusions (range,
0-9), p=0.00065). Pegfilgrastim was associated with reduced cost
of the treatment procedure compared with filgrastim (p=0.031). Pegfilgrastim
appears to be at least equivalent to filgrastim without additional
expenditure in myeloma patients treated with Mel200 and APBSCT.},
affiliation = {Department of Oncology, University Hospital Zürich, Rämistrasse 100,
8091 Zürich, Switzerland},
comment = {ZORA},
doi = {10.1007/s00277-010-1036-8},
file = {:/home/sarah/ispm/pubs/SamarasEtAl2011_HematologyPegfil.pdf:PDF},
issue = {1},
keyword = {Medicine},
owner = {sarah},
publisher = {Springer Berlin / Heidelberg},
timestamp = {2010.08.27}
}
@article{SamarasEtAl2011aso,
author = {Samaras, P and Breitenstein, S and \textbf{Haile}, S R and Stenner-Liewen,
F and Heinreich S and Feilchenfeldt, J and Renner, C and Knuth, A
and Pestalozzi, B and Clavien, P},
title = {{S}elective {I}ntra-arterial {C}hemotherapy with {F}loxuridine as
{S}econd or {T}hird {L}ine {A}pproach in {P}atients with {U}nresectable
{C}olorectal {L}iver {M}etastases},
journal = {Annals of Surgical Oncology},
year = {2011},
volume = {18},
pages = {1924--31},
number = {7},
abstract = {BACKGROUND: An outcome assessment was performed of patients with unresectable
colorectal liver metastases (CRLM) treated in second or third line
with floxuridine (FUDR)-based hepatic artery infusion (HAI).
METHODS: Twenty-three patients who were pretreated with systemic (immuno)chemotherapy
received FUDR-HAI alone or combined with systemic chemotherapy. We
reviewed patient charts and our prospective patient database for
survival and associated risk factors.
RESULTS: Patients received FUDR-HAI for unresectable CRLM from January
2000 to September 2010. Twelve patients (52\%) received concurrent
systemic chemotherapy.
Median overall survival (OS), progression-free survival (PFS), and
hepatic PFS were 15.6 months (range, 2.5-55.7 months), 3.9 months
(range, 0.7-55.7 months), and 5.5 months (range, 1.6-55.7 months),
respectively.
The liver resection rate after HAI was 35\%.
PFS was better in patients undergoing secondary resection than in
patients without resection (hazard ratio [HR] 0.21; 95% confidence
interval [95\% CI] 0.07-0.66; P = 0.0034), while OS showed a trend
toward improvement (HR 0.4; 95\% CI 0.13-1.2; P = 0.09).
No differences were observed in OS (P = 0.69) or PFS (P = 0.086) in
patients who received FUDR-HAI alone compared with patients treated
with combined regional and systemic chemotherapy.
No statistically significant differences were seen in patients previously
treated with one chemotherapy line compared with patients treated
with two lines.
Presence of extrahepatic disease was a negative risk factor for PFS
(liver-only disease: HR 0.03; 95\% CI 0.0032-0.28; P < 0.0001).
Toxicities were manageable with dose modifications and supportive
measures.
CONCLUSIONS: FUDR-HAI improves PFS and results in a trend toward improved
OS in selected patients able to undergo liver resection after tumor
is downsized.},
comment = {IF 4.13},
doi = {10.1245/s10434-010-1505-2},
file = {:/home/sarah/ispm/pubs/SamarasEtAl2011_SurgicalOncology.pdf:PDF},
owner = {sarah},
timestamp = {2010.10.06}
}
@article{SamarasEtAl2010,
author = {P Samaras and H Heider and S R \textbf{Haile} and U Petrausch and
N G Schaefer and R D Siciliano and A Meisel and A Mischo and M Zweifel
and A Knuth and F Stenner-Liewen and C Renner},
title = {{C}oncomitant statin use does not impair the clinical outcome of
patients with diffuse large {B} cell lymphoma treated with rituximab-{CHOP}},
journal = {Annals of Hematology},
year = {2010},
volume = {89},
pages = {783--7},
number = {8},
month = {August},
__markedentry = {[sarah]},
abstract = {Preclinical data indicated a detrimental effect of statins on the
anti-lymphoma activity of rituximab. We evaluated the impact of concomitant
statin medication on the response and survival of patients with diffuse
large {B} cell lymphoma ({DLBCL}) receiving rituximab-cyclophosphamide,
doxorubicin, vincristine, prednisone ({R-CHOP}) as first-line therapy.
Medical histories of patients with {DLBCL} who were treated with
{R-CHOP} as first-line therapy were assessed for concomitant statin
use, response after completion of chemotherapy, event-free survival
({EFS}), and overall survival ({OS}). Furthermore, 2-[(18)F]fluor-2-deoxyglucose
{(FDG)-PET/CT} results after completion of first-line therapy were
compared between the groups. Overall, 145 patients with {DLBCL} treated
with {R-CHOP} from January 2001 to December 2009 were analyzed. Twenty-one
(15%) patients received statins throughout therapy. Five-year {EFS}
was 67.3% in patients without statins compared with 79% in patients
receiving statins during {R-CHOP} ({HR}, 0.47; 95% {CI}, 0.15-1.54,
p = 0.2). Five-year {OS} was 81.4% for patients without statins compared
with 93.3% for patients taking statins ({HR}, 0.58; 95% {CI} 0.07-4.55,
p = 0.6). There were no statistically significant differences in
the rates of complete remissions between the two groups (75% in the
non-statin group versus 86% in the statin group, p = 0.45). A trend
toward a lower rate of complete metabolic responses in {FDG-PET/CT}
after chemotherapy was seen in patients without statin medication
compared with the patients taking statins (84% versus 92%, p = 0.068).
Concomitant statin use had no adverse impact on response to chemotherapy,
{EFS}, and {OS} in patients treated with {R-CHOP} for {DLBCL}.},
comment = {ZORA, IF 2.919},
doi = {10.1007/s00277-010-0926-0},
file = {:/home/sarah/ispm/pubs/SamarasEtAl2010_Hematology.pdf:PDF},
owner = {sarah},
timestamp = {2010.03.08}
}
@article{SamarasEtAl2010c,
author = {P Samaras and D Siciliano and S R \textbf{Haile} and U Petrausch
and A Mischo and B Pestalozzi and U Schanz and G St\"ussi and R Stahel
and C Renner and H Honegger and F Stenner-Liewen},
title = {{E}quivalence of pegfilgrastim and filgrastim in lymphoma patients
treated with {BEAM} followed by autologous stem cell transplantation.},
journal = {Oncology},
year = {2010},
volume = {79},
pages = {93--97},
__markedentry = {[sarah]},
abstract = {Objective: To evaluate the impact of pegfilgrastim on engraftment,
hospital stay and resources in patients with Hodgkin’s and non-Hodgkin’s
lymphoma after conditioning with high-dose {BEAM} followed by autologous
peripheral blood stem cell transplantation ({APBSCT}) compared with
filgrastim. Methods: We reviewed patient charts and our prospective
transplantation database for clinical data from the post-transplant
period. An integrated cost analysis, including the use of blood products
and length of hospital stay, was also performed. Results: Fourteen
(26\%) patients with Hodgkin’s lymphoma and 40 (74\%) patients with
non-Hodgkin’s lymphoma were analyzed. Thirty-four (68\%) patients
received single-dose pegfilgrastim (6 mg), and 20 (32\%) patients
received daily filgrastim (5 $\mu$g/kg) after {APBSCT}. No differences
were observed regarding duration of neutropenia grade 4 (pegfilgrastim
median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia
grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days;
p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75)
or length of hospital stay (16.5/16 days; p = 0.27) between the groups.
The use of pegfilgrastim resulted in 12\% higher treatment-related
costs when compared to filgrastim, without reaching statistical significance
(p = 0.38). Conclusion: Pegfilgrastim appears to be equivalent to
filgrastim after high-dose BEAM followed by APBSCT in the treatment
of lymphoma patients.},
comment = {IF 2.112, ZORA},
doi = {10.1159/000320604},
file = {:/home/sarah/ispm/pubs/SamarasEtAl2010_Oncology.pdf:PDF},
owner = {sarah},
timestamp = {2010.09.03}
}
@article{StoeckliEtAl2011,
author = {S St\"ockli and M Schukneckt and S K Haerle and S R \textbf{Haile}
and T F Hany and K Strobel},
title = {{I}nitial staging of the neck in head and neck squamous cell carcinoma:
{A} comparison of {CT}, {PET}/{CT}, and ultrasound-guided fine-needle
aspiration cytology},
journal = {Head and Neck},
year = {2011},
volume = {to appear},
abstract = {BACKGROUND The aim of this study was to compare imaging modalities
for staging the neck in a prospective cohort of patients evaluated
by {CT}, ultrasound with fine-needle aspiration cytology ({FNAC}),
and [(18) F]fluoro-2-deoxy-D-glucose ({FDG}) positron emission tomography
{(PET)/CT} with the histologic evaluation of the neck dissection
as the standard of reference.
METHODS: In all, 76 consecutive patients were prospectively enrolled.
RESULTS: Ultrasound-guided FNAC showed the highest level of agreement
with histology for exact N classification. Ultrasound-guided FNAC
showed the smallest percentage of overstaged patients, 7\%, versus
16\% with PET/CT, 13\% with CT, and 13\% with ultrasound. The rate
of understaged patients was comparable between the imaging modalities.
With regard to the endpoint N0 versus N+ there were no statistically
significant differences to be found.
CONCLUSIONS:
Ultrasound-guided FNAC seems to correlate best with histologic staging
compared with PET/CT and CT. None of the modality is reliable enough
to replace elective neck treatment in cN0 necks.},
doi = {10.1002/hed.21764},
file = {:/home/sarah/ispm/pubs/StoeckliEtAl2011.pdf:PDF},
owner = {sarah},
timestamp = {2010.10.06}
}
@article{SudanoEtAl2010,
author = {I Sudano and A J Flammer and D P\'eriat and F Enseleit and M Hermann
and M Wolfrum and A Hirt and P Kaiser and D Huerlimann and M Neidhart
and S Gay and J Nussberger and P Mocharla and U Landmesser and S
R \textbf{Haile} and R Corti and P M Vanhoutte and T F L\"uscher
and G Noll and F Ruschitzka},
title = {{A}cetaminophen increases {B}lood {P}ressure in {P}atients with {C}oronary
{A}rtery {D}isease},
journal = {Circulation},
year = {2010},
volume = {122},
pages = {1789--1796},
__markedentry = {[sarah]},
abstract = {Background: Since traditional non-steroidal anti-inflammatory drugs
are associated with increased risk for acute cardiovascular events,
current guidelines recommend acetaminophen as the first-line analgesic
of choice on the assumption of its greater cardiovascular safety.
Data from randomized clinical trials prospectively addressing cardiovascular
safety of acetaminophen, however, are still lacking, in particular
in patients at increased cardiovascular risk. Hence, it was the aim
of this study to evaluate the safety of acetaminophen in patients
with coronary artery disease.
Methods and Results: 33 patients with coronary artery disease were
included in this randomized, double-blind, placebo-controlled, crossover
study and received acetaminophen (1g TID) on top of standard cardiovascular
therapy for 2 weeks. Ambulatory blood pressure, heart rate, endothelium-dependent
and -independent vasodilatation, platelet function, endothelial progenitor
cells, markers of the renin-angiotensin-system, inflammation and
oxidative-stress were determined at baseline and after each treatment
period. Treatment with acetaminophen resulted in a significant increase
of mean systolic (from 122.4±11.9 to 125.3±12.0 mmHg, p=0.007 vs
placebo) and diastolic (from 73.2±6.9 to 75.4±7.9 mmHg, p=0.015 vs.
BL, p=0.008 vs. placebo) ambulatory blood pressure. On the other
hand, heart rate, endothelial function, early endothelial progenitor
cells and platelet function did not change.
Conclusions: As this study for the first time demonstrates that acetaminophen
induces a significant increase in ambulatory blood pressure in patients
with coronary artery disease, the use of acetaminophen should be
as rigorously evaluated as traditional {NSAID}s and {COX}-2 inhibitors,
in patients at increased cardiovascular risk in particular.
Trial Registration: ClinicalTrials.gov Identifier: NCT00534651},
comment = {ZORA , IF 14.816},
doi = {10.1161/circulationaha.110.956490},
file = {:/home/sarah/ispm/pubs/SudanoEtAl2010_Circulation.pdf:PDF},
owner = {sarah},
timestamp = {2010.09.03}
}
@inproceedings{JulianEtAl2005,
author = {T B Julian and S R Land and S \textbf{Haile} and E P Mamounas and
J P Costantino and N Wolmark},
title = {{I}s {S}entinel {N}ode {B}iopsy in {DCIS} {N}ecessary?},
booktitle = {Proceedings of the Society of Surgical Oncology},
year = {2005},
owner = {haile},
timestamp = {2007.12.01}
}
@inproceedings{land2008,
author = {S R Land and J A Kopec and M Lee and S R \textbf{Haile} and M W Ritter
and D Krag and S J Anderson and P A Ganz and N Wolmark},
title = {{Q}uality of life in breast cancer patients receiving sentinel-node
({SN}) biopsy alone or with axillary dissection ({AD}): {R}esults
from {NSABP} {P}rotocol {B}-32.},
booktitle = {Proceedings of the American Society of Clinical Oncology},
year = {2008},
volume = {26},
number = {9533},
abstract = {Background: NSABP B-32, a phase III randomized trial of SN resection
vs SN resection followed by AD (SNAD) in early stage breast cancer,
provided a unique opportunity to compare patient-reported outcomes
(PROs) arm function, symptoms, and quality of life (QOL). We report
the final treatment (TX) comparison of PROs. Methods: Women with
operable invasive breast cancer were eligible for B-32; those whose
SNs were negative were eligible for the PRO questionnaire sub-study.
Symptoms, arm-related disabilities, and QOL were assessed at baseline,
1 week after surgery (post-op), 2-3 weeks post-op, and 6, 12, 18,
24, 30, 36 months (mos). The primary endpoint, a multi- item ipsilateral
surgery symptom scale, was compared between TX at 6 and 12 mos using
two-sided, two-sample t-tests, with Bonferroni correction. An anticipated
accrual of 819 patients (pts) was calculated to yield 87% power for
the primary comparisons. We compared each PRO item by TX with repeated
measures analysis. We analyzed separately pts who received lumpectomy
vs mastectomy, and accounted for breast reconstruction and dominant
hand. Results: 749 pts enrolled in the PRO sub-study before B-32
completed accrual (358 SNAD, 391 SN). Arm symptoms were greater for
SNAD pts (effect size 0.4, p<0.0001 at 6 mos; effect size 0.25, p=0.006
at 12 mos). Over the complete time on study, SNAD pts had more difficulty
pushing large objects, lifting objects, reaching, and conducting
social and work activity (p<0.001). They were more likely to avoid
arm use and to experience symptoms (p=0.002 breast tenderness; p<0.001
all other items). The treatment difference persisted over time for
avoidance of arm use; arm or breast tenderness or swelling; and breast
pain, numbness, skin sensitivity, or tightness. Overall QOL was better
among SN pts (p<0.001) and improved over time (p<0.001). In both
groups, treatment was well tolerated by 6 mos: only 10% of pts reported
restriction of social/recreational activity, and overall QOL averaged
8 (scale 0-10). Conclusions: SN pts experienced significantly fewer
symptoms and activity limitations. However, long-term levels of symptoms
and limitations were low, and QOL was high, for both groups.},
owner = {sarah},
timestamp = {2010.01.06}
}
@inproceedings{OConnellEtAl2006,
author = {M J O'Connell and S Paik and G Yothers and J P Costantino and S R
\textbf{Haile} and J W Cowens and K M Clark and J Baker and J Hackett
and D Watson and N Wolmark},
title = {{R}elationship between tumor gene expression and recurrence in stage
{II/III} colon cancer: {Q}uantitative {RT-PCR} assay of 757 genes
in fixed paraffin-embedded ({FPE}) tissue.},
booktitle = {Proceedings of the American Society of Clinical Oncology},
year = {2006},
number = {3518},
owner = {haile},
timestamp = {2007.12.01}
}
@inproceedings{OConnellEtAl2005,
author = {M J O'Connell and N Wolmark and G Yothers and S \textbf{Haile} and
N Petrelli},
title = {{D}urable improvement in disease-free survival ({DFS}) and overall
survival ({OS}) for stage {II} or {III} colon cancer treated with
leucovorin-modulated fluorouracil ({FL}): 10-year follow-up of {N}ational
{S}urgical {A}djuvant {B}reast and {B}owel {P}roject ({NSABP}) protocol
{C}-03},
booktitle = {Proceedings of the American Society of Clinical Oncology},
year = {2005},
volume = {23},
number = {3511},
abstract = {Background: The 3-year results of NSABP protocol C-03 published in
1993 (Wolmark, et al J Clin Oncol 11:1879-87, 1993) indicated significant
improvement in DFS and OS for patients (pts) with stage II or III
colon cancer treated with postoperative FL compared to pts treated
with lomustine (MeCCNU), vincristine, and 5-FU (MOF). The present
analysis reports long-term results. Methods: Pts with stage II or
III (Dukes' B or C) colon cancer who had undergone a potentially
curative surgical resection were randomized postoperatively to receive
adjuvant chemotherapy with either MOF or FL (given on the ``Roswell
Park schedule'') for approximately 1 year. Results: 1081 pts (1044
eligible-96.6%) were randomized into C-03 from 1987-89. Of eligible
pts 986 (94.4%) had complete 10-year data (event or complete follow-up)
and 1022 (97.9%) had complete 5-year data. The 10-year Kaplan-Meier
estimates, relative risks from a stratified Cox model, and stratified
logrank p values (stratified for gender, # positive nodes [0, 1-4,
5+], and tumor location [right colon, non-right], as specified in
the protocol) for DFS and OS are shown below. Tests for interactions
of the stratification variables (gender, # positive nodes, and tumor
location) with treatment were not significant (p>0.16). Conclusions:
The 10-year results of NSABP C-03 confirm and extend the previously
published analysis, and indicate a highly significant and clinically
relevant improvement in DFS and OS for pts with stage II or III colon
cancer treated with FL compared to MOF. These data serve as a standard
for evaluation of new adjuvant regimens.},
owner = {haile},
timestamp = {2007.12.01}
}
@phdthesis{Haile2008,
author = {S R \textbf{Haile}},
title = {Inference on Competing Risks in Breast Cancer Data},
school = {University of Pittsburgh, Graduate School of Public Health},
year = {2008},
type = {Doctoral Dissertation},
abstract = {While nonparametric methods have been well established for inference
on competing risks data, parametric methods for such data have not
been developed as much. Because the cumulative incidence functions
are improper by their nature, flexible distribution families accommodating
improperness are needed for modeling competing data more accurately.
Additionally, different types of events present in a competing risks
setting may be correlated, yet current inference methods do not permit
inferring such data taking into account the correlation between failure
time distributions. This work first presents two new distributions
which are well-suited for modeling competing risks data. In existing
inference procedures for competing risks data, it appears that the
correlation between failure time distributions of competing events
are fixed as a constant. In the second part of this dissertation,
a novel approach is proposed which allows researchers to model competing
risks data by taking the correlation into account by estimating it.
The methods are illustrated by analyzing survival data from a breast
cancer trial of the National Surgical Adjuvant Breast and Bowel Project.
Simulation studies are also presented for each of the proposed new
distributions.
Public Health Significance: Competing risks occur often in many clinical
studies, and must be accounted for whenever researchers are interested
in only one type of event. For example, researchers may be interested
in investigating only local recurrences of breast cancer, but must
also take into account all other possible types of events as competing.
Parametric methods are not currently as well established as other
methods for competing risks data. Development of flexible parametric
inference procedures suitable for modeling competing risks data would
provide more accurate information, which will serve to improve patient
care in clinical settings.},
owner = {sarah},
timestamp = {2009.05.06}
}
This file was generated by bibtex2html 1.96.